About Us

Meet the Team behind NUP-CTx
NUP-CTx

Who We Are

NUP-CTx is a pioneering biopharmaceutical company dedicated to transforming cancer treatment through innovative approaches. Our team is composed of experts in oncology, nanotechnology, and drug development, all working together to revolutionize chemotherapy to reduce its drawbacks and increase its effectiveness.

our team of experts

Meet the NUP-CTx Team

Our team brings together a wealth of experience and expertise across diverse fields - biochemistry, medicine, biology, and nanotechnology. Driven by a shared passion for innovation, we are dedicated to transforming cancer treatment for the better.

  • Portrait Prof. Dr. Christian Schleuning
    Prof. Dr. Christian Schleuning Chief Executive Officer and Founder Experienced entrepreneur and business strategist. Founder of multiple ventures, drives NUP-CTx’s vision and growth.
  • Portrait Dr. Dr. Bernhard Schmitt
    Dr. Dr. Bernhard Schmitt Chief Medical Officer Renowned pathologist and clinical researcher. Oversees clinical strategy and regulatory affairs.
  • Portrait Johannes Karges
    Dr. Johannes Karges Chief Scientific Officer Award-winning chemist with expertise in bioinorganic chemistry. Developed NUP-1, leads innovation in drug delivery and chemotherapy.
  • Portrait Dr. Kai Blau
    Dr. Kai Blau Business Director Biotech business consultant with a strong background in genetics and research. Leads business operations and strategic partnerships.
  • Portrait Prof. Dr. Gerhard Gstraunthaler
    Prof. Dr. Gerhard Gstraunthaler Scientific Officer Accomplished researcher in cell physiology and biochemistry. Steers scientific research and innovations in drug development.
  • Portrait Raouf Belloum (B.Eng.)
    Raouf Belloum (B.Eng.) Scientist Specializing in the field of nanotechnology.

Our Journey

NUP-CTx was founded with a bold vision to transform the landscape of cancer treatment in chemotherapy. Since our inception, we have made remarkable progress in research and development, achieving promising preclinical results that pave the way for robust future clinical trials.

Investment Opportunities